Our top pick for
Intuitive Surgical, Inc is a medical instruments & supplies business based in the US. Intuitive Surgical shares (ISRG) are listed on the NASDAQ and all prices are listed in US Dollars. Intuitive Surgical employs 8,081 staff and has a trailing 12-month revenue of around USD$4.4 billion.
|52-week range||USD$360.5 - USD$826.81|
|50-day moving average||USD$768.8967|
|200-day moving average||USD$742.7448|
|Wall St. target price||USD$780.93|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$8.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Intuitive Surgical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Intuitive Surgical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Intuitive Surgical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, Intuitive Surgical shares trade at around 85x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Intuitive Surgical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.4823. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Intuitive Surgical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Intuitive Surgical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.3 billion.
The EBITDA is a measure of a Intuitive Surgical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.4 billion|
|Operating margin TTM||24.06%|
|Gross profit TTM||USD$2.9 billion|
|Return on assets TTM||6.27%|
|Return on equity TTM||11.83%|
|Market capitalisation||USD$88.3 billion|
TTM: trailing 12 months
There are currently 1.2 million Intuitive Surgical shares held short by investors – that's known as Intuitive Surgical's "short interest". This figure is 5.5% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Intuitive Surgical shares can be evaluated.
Intuitive Surgical's "short interest ratio" (SIR) is the quantity of Intuitive Surgical shares currently shorted divided by the average quantity of Intuitive Surgical shares traded daily (recently around 680365). Intuitive Surgical's SIR currently stands at 1.8. In other words for every 100,000 Intuitive Surgical shares traded daily on the market, roughly 1800 shares are currently held short.
However Intuitive Surgical's short interest can also be evaluated against the total number of Intuitive Surgical shares, or, against the total number of tradable Intuitive Surgical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intuitive Surgical's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Intuitive Surgical shares in existence, roughly 10 shares are currently held short) or 0.0105% of the tradable shares (for every 100,000 tradable Intuitive Surgical shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intuitive Surgical.
Find out more about how you can short Intuitive Surgical stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Intuitive Surgical.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 31.63
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Intuitive Surgical's overall score of 31.63 (as at 01/01/2019) is nothing to write home about – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Intuitive Surgical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.47/100
Intuitive Surgical's environmental score of 4.47 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Intuitive Surgical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.18/100
Intuitive Surgical's social score of 13.18 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Intuitive Surgical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.47/100
Intuitive Surgical's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Intuitive Surgical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Intuitive Surgical scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Intuitive Surgical has, for the most part, managed to keep its nose clean.
|Total ESG score||31.63|
|Total ESG percentile||59.52|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
We're not expecting Intuitive Surgical to pay a dividend over the next 12 months.
Intuitive Surgical's shares were split on a 3:1 basis on 6 October 2017. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Intuitive Surgical shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Intuitive Surgical shares which in turn could have impacted Intuitive Surgical's share price.
Over the last 12 months, Intuitive Surgical's shares have ranged in value from as little as $360.5 up to $826.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intuitive Surgical's is 1.0133. This would suggest that Intuitive Surgical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.